OBJECTIVES: The objective of this study was to characterize clinical outcomes when cefepime was used in a neonatal intensive care population. METHODS: Data were extracted from the medical records of all full-term (40 weeks gestational age) patients up to 2 months of age and preterm patients up to 48 weeks postmenstrual age admitted to the neonatal intensive care unit (NICU) at a freestanding children's hospital between January 1, 2010, and December 31, 2013, who received at least 48 hours of cefepime. The primary outcome measure was a positive clinical response as defined by a normalization of white blood cell count and/or culture clearance. RESULTS: Final analysis included 74 patients. Clinical response was evaluable in 43.2% (32 of 74) of courses. Of these, positive clinical response was observed in 81.3% (26 of 32). Overall patient mortality was 16.2% (12 of 74). Adverse effects (AEs) occurred in 14.9% (11 of 74) of courses. CONCLUSIONS: Cefepime can be used safely with reasonable clinical response in a NICU population, but additional studies are needed to further determine cefepime-associated clinical outcomes.
OBJECTIVES: The objective of this study was to characterize clinical outcomes when cefepime was used in a neonatal intensive care population. METHODS: Data were extracted from the medical records of all full-term (40 weeks gestational age) patients up to 2 months of age and preterm patients up to 48 weeks postmenstrual age admitted to the neonatal intensive care unit (NICU) at a freestanding children's hospital between January 1, 2010, and December 31, 2013, who received at least 48 hours of cefepime. The primary outcome measure was a positive clinical response as defined by a normalization of white blood cell count and/or culture clearance. RESULTS: Final analysis included 74 patients. Clinical response was evaluable in 43.2% (32 of 74) of courses. Of these, positive clinical response was observed in 81.3% (26 of 32). Overall patient mortality was 16.2% (12 of 74). Adverse effects (AEs) occurred in 14.9% (11 of 74) of courses. CONCLUSIONS:Cefepime can be used safely with reasonable clinical response in a NICU population, but additional studies are needed to further determine cefepime-associated clinical outcomes.
Authors: C Michael Cotten; Scott McDonald; Barbara Stoll; Ronald N Goldberg; Kenneth Poole; Daniel K Benjamin Journal: Pediatrics Date: 2006-08 Impact factor: 7.124
Authors: B Van Overmeire; K Smets; D Lecoutere; H Van de Broek; J Weyler; K Degroote; J P Langhendries Journal: N Engl J Med Date: 2000-09-07 Impact factor: 91.245
Authors: V Lima-Rogel; E L Medina-Rojas; R Del Carmen Milán-Segovia; D E Noyola; K Nieto-Aguirre; A López-Delarosa; S Romano-Moreno Journal: J Clin Pharm Ther Date: 2008-06 Impact factor: 2.512
Authors: Orlei Ribeiro de Araujo; Dafne Cardoso Bourguignon da Silva; Ana Regina Diegues; Ronaldo Arkader; Eloíza Aparecida Ferreira Cabral; Marta Rodriguez Afonso; Maria Eduarda Louzada; Andréa de Cássia Stéfano Albertoni Journal: Braz J Infect Dis Date: 2007-04 Impact factor: 1.949
Authors: X Sáez-Llorens; E Castaño; R García; C Báez; M Pérez; F Tejeira; G H McCracken Journal: Antimicrob Agents Chemother Date: 1995-04 Impact factor: 5.191
Authors: Christopher A Darlow; Renata M A da Costa; Sally Ellis; François Franceschi; Mike Sharland; Laura Piddock; Shampa Das; William Hope Journal: Paediatr Drugs Date: 2021-08-26 Impact factor: 3.022